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concentrations in platelets, where they
regulate the clotting process (Smith
et al., 2006).
The serendipitous concatenation of
efforts by the York and O’Shea labora-
tories (Mulugu et al., 2007; Lee et al.,
2007) enhances our appreciation of
inositol pyrophosphate biology. Differ-
ential roles for the two forms of PP-IP5
remain a mystery. However, it is ‘‘early
in the game,’’ and inositol pyrophos-
phates have already been implicated
in many processes fundamental to
life. The future is bright.
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An emerging view is that obesity causes metabolic problems when adipose tissue fails to meet the
increased demands for fat storage. A study in this issue of Cell Metabolism (Waki et al., 2007) has
identified harmine as a proadipogenic small molecule that promotes energy expenditure in white
adipose tissue and delays the onset of obesity-associated diabetes.Obesity is an important risk factor
in a complex metabolic syndrome
characterized by insulin resistance,
dyslipidemia, and hypertension and
is associated with diabetes and car-
diovascular complications. Current
pharmacological and behavioral ther-
apeutic strategies have had limited
success in controlling the prevalence
of obesity. Given the urgency of the
problem and the somber prospects
ahead, new strategies are required
to prevent the deleterious metabolic
effects associated with obesity.
There is little doubt that obesity
results from a positive imbalance
between energy intake and energy
expenditure. However, it is less clear
why being obese leads to diabetes
and cardiovascular complications. Anemerging view is that obesity causes
metabolic problems when adipose
tissue fails to meet the increased
demands for fat storage. Under these
circumstances, the excess fat that
cannot be efficiently and safely stored
in adipose tissue accumulates in other
metabolically relevant organs such as
muscle, liver, b cells, andmyocardium,
causing lipotoxicity and associated
metabolic complications.
Acceptance of the ‘‘lipotoxicity
hypothesis’’ leads to the apparently
paradoxical therapeutic approach of
promoting adipogenesis in obese in-
dividuals as a strategy to improve the
storage capacity of their adipose tis-
sue, thereby preventing the devel-
opment of complications associated
with obesity. This rationale is exploredCell MetabolbyWaki et al. (2007) in this issue ofCell
Metabolism. The authors performed
a high-throughput screen to identify
proadipogenic small molecules using
preadipocytes engineered with a re-
porter system activated by PPARg,
a key adipogenic transcription factor.
The idea was that small molecules
that selectively enhance PPARgwould
be identified through the activation
of this reporter. This imaginative ap-
proach paid off with the identification
of harmine.
Harmine, also known as telepathine
and banisterine, is a naturally occur-
ring b-carboline alkaloid found in
numerous plants including the Middle
Eastern plant harmal or Syrian rue (Pe-
ganum harmala), the South American
vine Banisteriopsis caapi (‘‘yage’’ orism 5, May 2007 ª2007 Elsevier Inc. 323
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PreviewsFigure 1. Effects of Harmine on PPARg Expression in db/db Mice
Harmine is a naturally occurring b-carboline alkaloid found in Syrian rue (Peganum harmala) and
other plants. A small-molecule library screen (Waki et al., 2007) has identified it as a proadipogenic
molecule that acts by inducing PPARg expression. Obese (db/db) mice treated with harmine show
a delay in the onset of diabetes, coincident with increased oxygen consumption and thermogen-
esis. A 2-fold increase in PPARg levels was selectively seen in white adipose tissue, while there
was a 50% decrease in PPARg levels in the liver and no change in muscle, brown adipose tissue,
or kidney. The effect of harmine on PPARg expression in the brain and pancreas is currently
unknown. Peganum harmala image reproduced from http://commons.wikimedia.org/.‘‘ayahuasca’’), tobacco, and passion
flowers. Among its many biochemical
actions is its ability to potently inhibit
monoamine oxidase (MAO) and so
prevent the breakdown of neurotrans-
mitters (serotonin, dopamine, norepi-
nephrine), hormones (melatonin), and
also hallucinogenic monoamines (psi-
locybin, dimethyltryptamine, mesca-
line). In fact, harmine has been used
for centuries in the Amazon and
Orinoco River basins for magico-
religious purposes as an active ingre-
dient in Ayahuasca, a psychotropic
tea. Intriguingly, Ayahuasca is still
used and advertised today for ‘‘people
with certain diseases or serious health
problems like obesity, epilepsy, arthri-
tis, kidney, liver, or stomach prob-
lems.’’ However, the scientific basis
for this claim is unknown.
Tontonoz and colleagues (Waki
et al., 2007) have discovered that324 Cell Metabolism 5, May 2007 ª2007harmine facilitates adipogenesis
in vitro through selective upregulation
of PPARg expression and inhibition of
Wnt signaling. These observations are
important for several reasons. First,
the identification of a small molecule
that selectively increases the amount
of PPARg expression in preadipocytes
and white adipose tissue (WAT) inde-
pendently of ligand activation is novel.
Furthermore, Waki et al. document
that gene dosage and protein levels
of PPARg are themselves important
factors controlling adipogenic poten-
tial independently and synergistically
with ligand activation of PPARg. The
second interesting finding is the confir-
matory observation that Wnt signaling
can be regulated in line with adipose
tissue expandability through its inter-
actions with PPARg. From this, it can
be inferred that Wnt signaling may
have a regulatory role controlling theElsevier Inc.degree and extent of PPARg inducibil-
ity and adipose tissue expandability.
How harmine inhibits Wnt signaling
and enhances PPARg is at present un-
clear. Harmine induction of PPARg
does not seem to be mediated by
known regulators of PPARg expres-
sion such as C/EBPs. However, the
possibility remains that PPARg pro-
moters are repressed by Wnt target
genes and/or that PPARg expression
itself inhibits Wnt signaling (Cawthorn
et al., 2007; Moldes et al., 2003; Liu
et al., 2006). Nonetheless, selective
modulation of Wnt signaling in WAT
may be a valid strategy to increase
adipose tissue expandability and im-
prove insulin sensitivity through its
effects on PPARg.
Waki et al. (2007) then went on to
validate the proadipogenic effect of
harmine in vivo. An unexpected finding
was that, despite its proadipogenic
effects in vitro, a high dose (30 mg/kg
twice per day) of harmine was required
to increase PPARg levels in WAT of
lean and obese mice. Interestingly,
no differences in body weight, adipose
mass, or food intake were observed.
However, despite this lack of effect
on adipose tissue mass, treatment
with harmine delayed the onset of dia-
betes in obese mice. Harmine-treated
mice exhibited increased energy ex-
penditure and improved insulin and
glucose tolerance. This was accompa-
nied by increased circulating adipo-
nectin levels and decreased lipid and
inflammatory profiles. The mechanism
behind this apparent paradox is that
the effect of harmine on adipose tis-
sue function in vivo is to promote in-
creased fatty acid oxidation selectively
in WAT (Figure 1) rather than to pro-
mote lipid storage. Mechanistically,
this twist was not completely unex-
pected since it is known that PPARg
can, in the presence of specific co-
activators such as PGC-1a and/or
appropriate sympathetic stimuli, in-
duce the genetic program required for
mitochondrial biogenesis and ther-
mogenesis characteristic of brown
adipose tissue (BAT) in vivo. None-
theless, the tissue-specific response
identified by this pharmacological treat-
ment highlights the potential for thera-
peutically improving carbohydrateme-
tabolism through the modulation of
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Previewsadipocyte PPARg and circumvents
the hepatic and renal side effects
previously associated with PPARg
activation.
Based on all of these observations,
several inferences can be made. The
first is a cautionary reminder about
the pharmacological translatability
in vivo of the results from in vitro
screening strategies. Although the
original hypothesis was that strategies
promoting adipose tissue expansion
might prevent the metabolic syn-
drome, strictly speaking, what this
report shows is that increased fat
oxidation may be sufficient. This ob-
servation does not invalidate proadi-
pocyte screens for identifying lead
compounds, nor does it contradict
the lipotoxic theory, since an alter-
native strategy for decreasing the lipo-
toxic insult is to eliminate the excess of
lipids through their oxidation. In this
context, it could be argued that har-
mine not only increases the adipo-
genic potential but, more importantly,
decreases the demands for lipid
storage.
The results from Waki et al. (2007)
also suggest that levels of PPARg
may be an important determinant of
the white versus brown phenotype.
This agrees with a recent observation
that mice expressing a dominant-
negative mutant of PPARg maintain
normal white adipocytes in WAT but
have fewer brown adipocytes in this
depot (Gray et al., 2006). It is unclear
by what mechanism a BAT-like pheno-type is induced in WAT of harmine-
treated animals and whether this is
sufficient to explain the improved met-
abolic profiles. Nevertheless, given
that harmine is a known inhibitor of
MAO and cyclin-dependent kinases
and also binds imidazoline and 5-hy-
droxytryptamine receptors, numerous
additional mechanisms may also be
contributing to its beneficial in vivo ef-
fects. For example, chronic MAO inhi-
bition could increase sympathetic
tone, while imidazoline receptor bind-
ing and activation may enhance insulin
secretion by b cells (Cooper et al.,
2003; Morgan et al., 2003). Addition-
ally, it is noteworthy that the tissue-
specific actions of harmine are most
likely determined by a combination of
the differential expression of these
binding proteins and the tissue-spe-
cific uptake and inactivation of har-
mine. In any case, it would be informa-
tive to know if PPARg is also induced
in the brain of these animals and ac-
counts for some of the neurological
phenotypes of harmine (Inestrosa
et al., 2005). The adipose tissue spec-
ificity of harmine-induced effects on
PPARg requires further clarification.
The fact that harmine induces changes
in Wnt target genes in other organs
without affecting PPARg levels sug-
gests tissue specificity but warns of
possible important side effects of har-
mine or other potential drugs using
a similar mechanism of action.
In the twists and turns that follow
proadipogenic screenings of smallCell Metabolmolecules, unexpected in vivo results
can open up exciting new avenues
for metabolic research. Although har-
mine itself is not a suitable antiobesity
or antidiabetic drug, identification of
its WAT-specific pro-oxidative effects
may lead to novel therapeutic strate-
gies to counteract the deleterious met-
abolic effects associated with obesity.
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